Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose

• DOI: 10.1111/ijcp.12089
• Publication Date: 2013-03-29T10:07:42Z
• Authors: V. Sazonov; D. Maccubbin; C. McCrary Sisk; P. L. Canner
• Keywords: Niacin; Impaired fasting glucose; Post-hoc analysis

Background: This post hoc analysis from the Coronary Drug Project (CDP) evaluated effects of niacin vs. placebo on incidence new onset type 2 diabetes mellitus (T2DM) and cardiovascular event rates in patients with normal impaired fasting glucose (IFG). Methods: The CDP was a randomised, placebo-controlled clinical trial lipid-modifying agents men previous myocardial infarction. Normoglycaemia IFG were defined as plasma (FPG) < 5.6 mmol/l FPG ≥ but 7.0 mmol/l, respectively. New T2DM by 1 following: diagnosis T2DM, use an antihyperglycaemic therapy, or two values mmol/l. Results: higher (16.5%) compared those normoglycaemia (5.4%), slightly both normoglycaemic (6.8% 4.9%; p = 0.07) (19.8% 15.2%; 0.05) patients. Consistent analyses, benefit independent baseline glycaemic status (normal, IFG, T2DM) change level to year 1. Conclusion: Despite modest increase risk long-term there is potential niacin.